BRILINTA (AstraZeneca Pharmaceuticals LP)
Welcome to the PulseAid listing for the BRILINTA drug offered from AstraZeneca Pharmaceuticals LP. This P2Y12 Platelet Inhibitor [EPC],Phenylalanine Hydroxylase Activators [MoA],Decreased Platelet Aggregation [PE],P2Y12 Receptor Antagonists [MoA],Cytochrome P450 3A4 Inhibitors [MoA],Cytochrome P450 3A5 Inhibitors [MoA],P-Glycoprotein Inhibitors [MoA] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
| LABELER NAME / MANUFACTURER: | AstraZeneca Pharmaceuticals LP |
| NON-PROPRIETARY NAME: | Ticagrelor |
| SUBSTANCE NAME: | TICAGRELOR |
| TYPE: | HUMAN PRESCRIPTION DRUG |
| PHARMA CLASS: | P2Y12 Platelet Inhibitor [EPC],Phenylalanine Hydroxylase Activators [MoA],Decreased Platelet Aggregation [PE],P2Y12 Receptor Antagonists [MoA],Cytochrome P450 3A4 Inhibitors [MoA],Cytochrome P450 3A5 Inhibitors [MoA],P-Glycoprotein Inhibitors [MoA] |
| ROUTE: | ORAL |
| DOSAGE FORM: | TABLET |
| MARKETING CATEGORY NAME: | NDA |
| START MARKETING DATE: | 2015-09-04 |
| END MARKETING DATE: | 0000-00-00 |
BRILINTA HUMAN PRESCRIPTION DRUG Details:
| Item Description | BRILINTA from AstraZeneca Pharmaceuticals LP |
| LABELER NAME: | AstraZeneca Pharmaceuticals LP |
| DEA SCHEDULE: |
|
| ACTIVE STRENGTH: | 60(mg/1) |
| START MARKETING DATE: | 2015-09-04 |
| END MARKETING DATE: | 0000-00-00 |
| PRODUCT ID: | 0186-0776_336d8857-17f0-48f3-8db8-240600f18953 |
| PRODUCT NDC: | 0186-0776 |
| APPLICATION NUMBER: | NDA022433 |
Other TICAGRELOR Pharmaceutical Manufacturers / Labelers:
